Family members and friends have begun identifying many of the 16 American service members who died on Monday when their plane crashed in rural Mississippi.
NYS Entity Status
NYS Filing Date
JUNE 16, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - M2M ST. MARKS CORP.
AROUND THE WEB
- Marine Corps Plane Crash: The Victims
By THE NEW YORK TIMES - Thursday Jul 13, 2017
- Could the Rockaways Survive Another Sandy?
By LUIS FERRÉ-SADURNÍ - Thursday Jul 13, 2017
Residents are bracing for the worst, wondering whether measures taken so far are enough to keep devastation of the Queens community at bay.
- Tim Tebow helps St. Lucie Mets set attendance mark
By Post Sports Desk - Saturday Aug 5, 2017
Sandy Alderson recently said the “entertainment” factor was a big reason why the Mets signed Tim Tebow to a minor-league deal. And he was right: Tebow entertains and brings in the fans. The St. Lucie Mets announced Friday that they set a new single season home attendance record of 108,057. “Look, we signed him because...
- Insurance Giant Aetna Is Leaving Hartford for New York City
By SARAH MASLIN NIR - Thursday Jun 29, 2017
Aetna will move to new headquarters in Manhattan, drawn by New York’s emergence as a digital powerhouse, as well as financial incentives.
- FDA advisers review data on potential 1st US gene therapy
By LINDA A. JOHNSON, AP Medical Writer - Wednesday Jul 12, 2017
Cancer experts who advise government regulators are reviewing what could be the first gene therapy approved in the U.S.The Food and Drug Administration panel is holding a hearing Wednesday to discuss the treatment developed by the University of Pennsylvania and Novartis Corp. The drugmaker is seeking approval to use the one-time treatment for children and young adults with advanced leukemia.
- Novel leukemia treatment could be 1st US gene therapy
By Associated Press - Thursday Jul 13, 2017
A treatment for a common childhood blood cancer could become the first gene therapy available in the U.S. A Food and Drug Administration advisory panel voted 10-0 on Wednesday in favor of the leukemia treatment developed by the University of Pennsylvania and Novartis Corp. The FDA usually follows recommendations from its expert panels, but isn’t...